Click here to view a write-up of the virtual event HEALTHY AGING AND ALZHEIMER'S DISEASE: Detecting the genes that protect us from Alzheimer's.
Wednesday, September 16, 2020
12:00PM - 1:00PM (ET)
Why is it that many people's brains have been found to have the signature defects of Alzheimer's disease, yet they never showed the thinking and memory problems of the disease while they were alive? Some people, it seems, are protected from Alzheimer's and some aren't. Join The Jackson Laboratory's Chief Financial Officer, Doug Abbott, for a virtual conversation with JAX scientist and Alzheimer's expert, Catherine Kaczorowski, Ph.D., about her research into the genetic factors that are protecting some people's brains and memories from Alzheimer's.
For questions about upcoming events, please contact Marisa Marinelli by email (email@example.com) or by phone at (207) 288-6753.
Doug Abbott, M.B.A., C.P.A., Chief Financial Officer
Doug Abbott joined the Jackson Laboratory in September 2018. In his current role, Doug provides strategic leadership, direction and management for all financial and risk management activities.
Before coming to JAX, Doug served in several senior finance leadership roles at WEX, Inc., a global provider of payment processing systems headquartered in South Portland, Maine, including Vice President of the Americas, Vice President of International Finance, and most recently as the Vice President and Senior Financial Officer of WEX’s Global Fleet business. Prior to WEX, Doug held several finance leadership roles in increasing responsibility at Thermo Fisher Scientific, and Elmet Technologies. Doug also practiced public accounting at Ernst & Young in their Kansas City office, where he managed several large clients, including Berkshire Hathaway and AMC Entertainment. Doug holds a B.S. degree in Chemical Engineering from the University of New Hampshire, as well as a M.B.A., also from the University of New Hampshire. Doug also is a Certified Public Accountant (inactive).
Catherine Kaczorowski, Ph.D., Associate Professor, Evnin Family Chair in Alzheimer's Research
Professor Kaczorowoski's research focus is to identify early causative events that underlie cognitive deficits associated with ‘normal’ aging and Alzheimer’s disease. Using multidisciplinary approaches that combine systems genetics with innovative high resolution and high throughput membrane proteomics, viral-based gene transduction approaches, behavioral assays, in vitro brain slice electrophysiology and in vivo electrophysiological recordings in freely behaving mice, my research seeks to identify and understand how genetic factors and misregulated membrane proteins in the hippocampus of aging and AD mouse models alter hippocampal neuron excitability, functional connectivity of hippocampal neural networks, and memory.
Alzheimer’s is the sixth leading cause of death in the U.S., and currently no treatments are available that prevent or slow the disease. The race is on to develop accurate tools to diagnose Alzheimer’s before symptoms occur, and find effective treatments to prevent the devastating destruction of the disease.
JAX Alzheimer's experts, Gareth Howell, Ph.D., Associate Professor, and LuAnn Ballesteros, Vice President of External and Government Affairs, explore how new research approaches and collaborations can change the future of Alzheimer's diagnosis, treatment, and prevention.
Scientists at The Jackson Laboratory (JAX) are harnessing powerful genomic technologies to identify biological markers of Alzheimer’s disease. It’s a bold approach, aiming to identify people at risk for Alzheimer’s disease years before symptoms emerge.